Aegle Therapeutics is a privately-held biotechnology company developing a first in class therapy using extracellular vesicles (EVs), including exosomes, secreted by allogeneic bone marrow derived mesenchymal stem cells. Aegle's platform technology is initially being developed to treat dystrophic epidermolysis bullosa ('DEB'), a rare pediatric skin blistering disorder. Aegle's IND for DEB has been cleared by the FDA and the Company expects to enter the clinic by the 2H of 2020. Aegle believes its platform technology, based on intellectual property licensed from the University of Miami and developed by Chief Scientific Officer, Evangelos Badiavas, M.D., Ph.D., has a broad range of potential indications.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/07/20 | $4,000,000 | Venture |
DeepWork Capital DEFTA Healthcare Technologies New World Angels  Ocean Azul Partners Tellus BioVentures | undisclosed |
